International Journal of Radiation Oncology*Biology*Physics
Clinical investigationLungAcute tumor vascular effects following fractionated radiotherapy in human lung cancer: In vivo whole tumor assessment using volumetric perfusion computed tomography
Introduction
Nearly 50% of patients with cancer will undergo radiotherapy as part of their treatment (1). For lung cancer, radiotherapy is a major treatment modality; radical radiotherapy is offered for potentially curable tumors, and palliative radiotherapy for symptomatic relief of advanced disease. However, treatment failure will occur in a not insignificant number of patients, and manipulation of the tumor vasculature has emerged as a promising therapeutic strategy over the past few years (2). Antiangiogenic agents that impede tumor neovascularization and vascular disrupting agents that target established tumor blood vessels are currently in clinical trials, and are being integrated with fractionated radiotherapy regimens, with the aim of improving treatment effectiveness.
There has been little human data on the acute effects of radiation on tumor vasculature. Recent preclinical data have indicated that the tumor response to radiation may be regulated by the degree of apoptosis in tumor endothelial cells, suggesting that the tumor vasculature may be an important therapeutic target for radiation (3). There is also evidence that radiation-induced tumor regression may involve destruction of tumor vessels. It is also well recognized that tumor perfusion, through its effects on oxygenation, plays an important role in modulating responses to radiotherapy (4). Thus, further studies of the in vivo tumor vascular effects of ionizing radiation are warranted.
To date, the acute in vivo effects of fractionated radiotherapy on tumor vessels have not been evaluated for human lung cancer. Assessment of the acute tumor vascular effects of ionizing radiation in human tumors is needed to corroborate data suggesting that the tumor vasculature may be an important therapeutic target for radiation. It is also important to establish a baseline for future evaluation of combined therapy with antiangiogenic and vascular disrupting drugs in human lung cancer. Thus the aim of this study was to measure in vivo the acute vascular effects of fractionated radiotherapy on an entire human lung cancer using a volumetric perfusion computed tomography (CT) technique.
Section snippets
Patients
Institutional review board approval was obtained, with explicit approval for radiation exposure of patients for research purposes as required under the Ionizing Radiation (Medical Exposure) Regulations. Each patient gave written informed consent; this included information on the radiation exposure from both the CT examinations (7.5 mSv per examination) and subsequent radiotherapy (27 Gy total dose). Sixteen patients (9 males, 7 females) with histologically proven, inoperable non–small-cell lung
Measurement reproducibility
Permeability values were transformed by natural logarithm because the variability of the value was dependent on the mean. The repeatability statistics are summarized in Table 1. From our data, the dSD values for vascular blood volume and logarithmically transformed vessel permeability were 1.05 mL/100 mL and 0.13 mL/100 mL/min, respectively. For a group of 16 patients, any change in tumor vascular blood volume of more than ± 9.4% as a consequence of treatment would be over and above intrinsic
Discussion
Perfusion CT provides a robust, accessible, and noninvasive method for measuring tumor vascularity, including blood flow, blood volume, and permeability depending on the mathematical algorithms used (8, 9), and has been shown to correlate with histologic markers of angiogenesis in lung cancer (10, 11). Although CT measurements have been limited to small tumor volumes previously, current improvements in CT technology have enabled quantitative vascular assessment of large tumor volumes
Acknowledgments
The authors are grateful to Ernst Klotz and Heinz Fichte (Siemens Medical Solutions, Forchheim, Germany) who developed the prototype perfusion software used for image analysis; Pat Fernie and radiographers at the Paul Strickland Scanner Centre for performing the computed tomography scans; and Jane Taylor for statistical advice.
References (25)
- et al.
Application of CT in the investigation of angiogenesis in oncology
Acad Radiol
(2000) - et al.
Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: Role of reoxygenation, free radicals, and stress granules
Cancer Cell
(2004) - et al.
Evidence for mRNA expression of vascular endothelial growth factor by X-ray irradiation in a lung squamous carcinoma cell line
Cancer Lett
(1998) - et al.
Early reoxygenation in tumors after irradiation: Determining factors and consequences for radiotherapy regimens using daily multiple fractions
Int J Radiat Oncol Biol Phys
(2005) - et al.
Eur J Radiol
(1999) - et al.
Chemoradiation schedules—what radiotherapy?
Eur J Cancer
(2002) - et al.
Recent progress in defining mechanisms and potential targets for prevention of normal tissue injury after radiation therapy
Int J Radiat Oncol Biol Phys
(2005) - et al.
Cancer statistics 2005
CA Cancer J Clin
(2005) - et al.
Angiogenesis and lung cancer: Prognostic and therapeutic implications
J Clin Oncol
(2005) - et al.
Tumor response to radiotherapy regulated by endothelial cell apoptosis
Science
(2003)
The histological structure of some human lung cancers and the possible implications for radiotherapy
Br J Cancer
Lung cancer perfusion at multi-detector row CT: Reproducibility of whole tumor quantitative measurements
Radiology
Cited by (77)
Volume-staged gamma knife surgery for the treatment of large skull base meningioma surrounding the optical apparatus: A snowman-shape design
2017, Journal of the Chinese Medical AssociationTargeted radionuclide therapy in combined-modality regimens
2017, The Lancet OncologyEffect of particle size on the biodistribution, toxicity, and efficacy of drug-loaded polymeric nanoparticles in chemoradiotherapy
2017, Nanomedicine: Nanotechnology, Biology, and MedicineRadiotherapy and targeted therapy/immunotherapy
2016, Cancer/Radiotherapie
The Marie Curie Research Wing is supported by Cancer Research UK. This work is further supported by a project grant from the Royal College of Radiologists.
Conflict of interest: none.